iology to change over time, Giordano says.While SEER data does not code for treatment, we hypothesize that two contributing factors for the growing disparity are lack of access to health care and lack of access to newer types of treatment for Stage IV breast cancer, such as targeted therapies, including the drug Herceptin and the class of drugs known as aromatase inhibitors.BackgroundThe study